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Background: In addition to its important metabolic activities, vitamin D also contributes to the regulation of the
immune system. The aim of this study was to assess the relationship between hypovitaminosis D and disease
activity in Moroccan children with juvenile idiopathic arthritis (JIA).
Methods: In this cross-sectional study, forty children with JIA were included, all having been diagnosed according
to the classification criteria of International League of Associations for Rheumatology (ILAR). The children underwent
anthropometric assessment and clinical evaluation. Disease activity was measured using the Disease Activity Score
in 28 joints (DAS28) for polyarticular and oligoarticular JIA and the Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI) for enthesitis-related arthritis. Serum 25-hydroxyvitamin [25(OH)D] D2 and D3 were measured using radio-
immunoassay (RIA). Hypovitaminosis D was defined as serum 25(OH)D <30 ng/ml.
Results: The average age of participants was 11 years ± 4.23. Hypovitaminosis D was observed in 75% of patients.
In univariate analyses, 25(OH)D levels were negatively associated with DAS28 for polyarticular and oligoarticular JIA.
No significant relationship was found between 25(OH)D levels and BASDAI for juvenile spondylarthropathy. In
multivariate linear regression analysis, no association persisted between 25(OH)D levels and DAS28.
Conclusions: Our study suggested that serum levels of vitamin D were low in Moroccan children with JIA disease.
Future studies with a larger population are needed to confirm our results.
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In recent years, vitamin D has attracted a significant
amount of attention from researchers [1]. It is estimated
that as many as one billion people worldwide suffer from
vitamin D deficiency or insufficiency, and this was
shown to be prevalent across all age groups, genders,
and geographic regions [2-4]. In addition to its import-
ant metabolic activities, vitamin D also contributes to
the regulation of the immune system [5]. It has been
suggested recently that vitamin D is an environmental
factor that, by modulating the immune system, affects
the prevalence of autoimmune diseases [6]. The immune* Correspondence: drbouaddilham@yahoo.fr
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reproduction in any medium, provided the ormodulatory effects of this vitamin have been subject to
extensive examination, leading to recent speculation that
it may play a role in select inflammatory diseases [7]. In
adults, many studies have shown an inverse association
between disease activity and serum levels of 25(OH)D
[5]. For example, serum 25(OH)D levels were found to
correlate inversely with disease activity in adults with
rheumatoid arthritis (RA), in those with newly diagnosed
inflammatory polyarthritis [8,9], and in ankylosing spon-
dylitis [10]. Pelajo et al. found that 20% percent of pa-
tients who attended a pediatric rheumatology clinic were
vitamin D deficient [11]. Juvenile idiopathic arthritis
(JIA) is the most common chronic rheumatic disorder of
childhood [12]. It is a heterogeneous and multifactorial
autoimmune disease characterized by persistent joint
inflammation, which manifests as swelling, pain andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Socio-demographic and clinical characteristics of
the patients
Females1 18 (45)
Age (years)2 11 ± 4.23
Subtype of JIA1
Systemic-onset arthritis 11 (27.5)
Oligoarthritis 9 (22.5)
Rheumatoid factor- positive polyarthritis 17 (45.5)
Rheumatoid factor- negative polyarthritis 1 (2.5)
Enthesitis-related arthritis 1 (2.5)
Psoriatic arthritis 1 (2.5)









1Number and percentage N (%); 2mean and standard deviation; 3median and IQR
interquartile range; NSAID: non-steroidal anti-inflammatory drugs; CHAQ:
Childhood Health Assessment Questionnaire.
Table 2 Characteristics of disease activity
Tender joints1 3 [1–8]
Swollen joints1 1 [0–3]
ESR (mm/h)1 34.5 [25–55]
CRP (mg/l)1 21.5 [11–41]
Patient global assessment (cm)1 25 [10–40]
DAS282 4.84 ± 1.27
BASDAI1 1.4 [0–2.6]
1median and IQR interquartile range; 2mean and standard deviation; DAS28:
disease activity score in 28 joints; ESR: Erythrocyte sedimentation rate; CRP:
C-reactive protein; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index.
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regarding the association between disease activity and
serum levels of 25(OH)D in children with JIA. The aim
of this study was to examine the association between
serum levels of 25(OH)D and disease activity in Mo-
roccan children with JIA.
Methods
Between June and August 2011, we recruited patients di-
agnosed with JIA who met the classification criteria of
the International League of Associations for Rheumatol-
ogy (ILAR) [14]. The Departments of Rheumatology and
Pediatrics of the University Hospital of Rabat-Salé car-
ried out this cross-sectional study. Patients were ex-
cluded if they had either an additional chronic disease or
were receiving treatment (except corticosteroids) that
could influence vitamin D status. No patient was taking
vitamin D supplementation. The Ethics Committee of
university hospital center Ibn Sina approved this study
and all participants’ parents provided written consent.
A detailed questionnaire was completed based on the
information obtained from the patient’s medical records
and by interviewing all of the participants or their par-
ents for children under 10 years. Collected data included
age, sex, subtype of JIA, disease duration, and medication
(corticosteroid, non-steroidal anti-inflammatory drugs
(NSAIDs), methotrexate, sulfassalazine and biological
drugs). Erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP) and the patient’s responses to the Child-
hood Heath Assessment Questionnaire (CHAQ - trans-
lated and certified in Arabic) [15]. Disease activity was
measured using the Disease Activity Score in 28 joints
(DAS28) for polyarticular and oligoarticular JIA [16,17],
and the Bath Ankylosing Spondylitis Disease Activity
Index (BASDAI – translated and certified in Arabic) for
juvenile spondylarthropathy [18].
Serum 25-hydroxyvitamin D
Serum concentrations of calcium, phosphate, alkaline
phosphatase, and 25-hydroxyvitamin D2 and D3 [25
(OH)D] were measured. All serum samples were taken
during the summer when vitamin D levels would nat-
urally be the highest, and measurements were done in
the same laboratory. Serum 25(OH)D was measured in
nanograms per milliliter using radioimmunoassay. We
defined levels <20 ng/ml (50 nmol/L) as vitamin D de-
ficiency; levels from 20–29 ng/ml (50–72 nmol/L) as
vitamin D insufficiency; and levels ≥30 ng/ml (75 nmol/L)
as adequate [2,19].
Statistical analysis
Analyses were performed using the software program SPSS
(Windows Version 13.0, SPSS Inc., Chicago, IL). Descrip-
tive statistics were used to assess the demographic variablesand characteristics of disease activity. A linear regression
was used to analyze the association between serum 25
(OH)D levels and any variables that could influence serum
25(OH)D levels, including age, BMI, duration of JIA, JIA
subtype, CHAQ, Patient global health, Tender joints, Swol-
len joints, DAS28, ESR, and BASDAI and Medications
used. DAS28 and its components (except swollen joints)
were included in multivariate analysis. P values ≤ 0.05 were
considered significant.
Results
Forty patients, 18 females (45%), with JIA were included
in this cross sectional study. The average age of partici-
pants was 11 years ± 4.23. The median disease duration
was 2 years [1-5]. The most common JIA subtypes were
Figure 1 Characteristics of 25-hydroxyvitamin D.
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(27.5%), and oligoarticular (22.5%). Twenty three chil-
dren (57.5%) were receiving corticosteroid. Twenty-two
patients (55%) were using disease-modifying anti-rheumatic
drugs (DMARDs). Three children (7.5%) were under
biological drugs. Patients’ characteristics are presented
in Table 1.
Twenty-one patients (52.5%) were considered to have
an active disease, with 48% patients having a high dis-
ease activity. The average DAS28 was 4.84 ± 1.27. Me-
dian BASDAI was 1.4 [0–2.6]. Characteristics of disease
activity are presented in Table 2. 75% of children hadTable 3 Linear regression analysis between 25(OH)D levels an
Univariate analysis
β CI
Age (years) −0. 32 (−1.15, 0.51)
BMI −0.15 (−0.96, 0.65)
Time since JIA onset (years) −0.52 (−1.74, 0.69)
JIA subtype
Oligoarthritis 0
Systemic-onset arthritis −0.92 (−8.81, 6.96)
Polyarticular forms −0.55 (−7.61, 6.50)
CHAQ −3.28 (−7.31, 0.75)
Patient global health (cm) −0.17 (−0.35, −0.004)
Tender joints −0.79 (−1.47, −0.10)
Swollen joints −0.67 (−1.78, 0.42)
ESR (mm/h) −0.14 (−0.28, 0.004)
DAS28 −3.87 (−7.67, −0.07)
BASDAI −1.88 (−6.40, 2.62)
Medications used:
NSAID 1.45 (−6.67, 9.57)
Corticosteroid 1.08 (−6.04, 8.2)
Methotrexate −3.63 (−10.73, 3.46)
Sulfassalazine −0.04 (−9.91, 9.83)
Biologics 1.56 (−11.81, 14.94)
CI: confidence interval at 95%; BMI: body mass index; DAS28: disease Activity Score in
Index; NSAID: non-steroidal anti-inflammatory drugs; CHAQ: Childhood Health Assessmhypovitaminosis D [25(OH)D <30 ng/ml] (Figure 1). The
mean serum 25(OH)D level was 22.21 ng/ml ±10.87.
Levels of serum calcium, phosphate and alkaline phos-
phatase were normal in all patients.
Serum 25(OH)D levels were associated with DAS28
(p = 0.04 , β: −3.87, CI: (−7.67,-0.07) ). In the univariate
linear regression analysis, serum 25(OH)D levels were
associated with the following disease activity compo-
nents: ESR (p = 0.05, β: −0.14, CI: (−0.28,0.004)), tender
joints (p = 0.02, β: −0.79, CI (−1.47,-0.10)), and patient
global health (p = 0.04, β: −0.17, CI: (−0.35,-0.004)). In
multivariate linear regression analysis, no association
persisted between 25(OH)D levels and DAS28, ESR, ten-
der joints and patient global health. Number of swollen
joints was not used in the multivariate analysis because
it was not associated in the univariate linear regression ana-
lysis. Linear regression analysis between 25(OH)D levels
and participant characteristics is presented in Table 3.
Discussion
To the best of our knowledge, this is the first study in
Morocco, let alone in an Arabic and/or African country,
concerning hypovitaminosis D and disease activity in chil-
dren with JIA. When measured by DAS28, our results
showed an association between serum 25(OH)D levelsd participant characteristics
Multivariate analysis







0.04 −0.6 (−0.50, 0.38) 0.7
0.02 −1.23 (−3.76, 1.30) 0.3
0.2
0.05 −0.21 (−0.66, 0.23) 0.3







28 joints; ESR: Erythrocyte sedimentation rate; BASDAI: Bath AS Disease Activity
ent Questionnaire.
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relationship was found between BASDAI and 25(OH)D.
In multivariate linear regression, no association persisted
between 25(OH)D and disease activity components. The
small sample size of children; and the duration of illness
may explain this result. With the average onset time being
two years earlier, many of the children were taking medi-
cation that would modify the disease course. One study
also examining serum 25(OH)D levels and disease activity
in children and adolescents was performed by Pelajo et al.,
which found no association between the two variables
[20]. Patel et al. examined patients who had been recently
diagnosed in the early stage of inflammatory polyarthritis,
45% of whom were classified as having RA for no more
than 1 year [8]. Like us, they found a strong inverse asso-
ciation between baseline levels of both serum 25(OH)D
and disease activity, as assessed by DAS28. Two studies
completed in the last five years have highlighted the asso-
ciation between autoimmunity and vitamin D deficiency
[21,22]. Cutolo et al. reported that vitamin D is implicated
in the pathogenesis of different autoimmune disease [23].
Those results support the research of numerous other
studies, which found that the immune system is character-
ized by low serum levels of vitamin D that correlate to the
severity of the disease [4,24]. In unadjusted analysis, a
2010 study found that vitamin D concentrations were
inversely associated with baseline pain (p = 0.04), swol-
len joints (p = 0.04), and DAS28 (p = 0.05) in African
American patients with early stage RA [7]. When compar-
ing RA patients to healthy controls, 5 studies revealed
lower levels of 25(OH)D in the patients [7,22,25,26], while
2 studies did not find such a distinction [27,28]. Looking
beyond RA to other autoimmune disease, Becker et al.
found that 34 of 57 systemic lupus erythematosus (SLE)
patients who had high disease activity also had severe vita-
min D depletion [29].
Our study showed a high level of hypovitaminosis D
(75%) in children with JIA. In studies comparing healthy
children to children with JIA, vitamin D deficiency has
been noted in children with JIA [30]. Epidemiological
data indicates that up to 60% of patients with RA have
25(OH)D levels <50 nmol/L, and 16% have levels would
be classified as vitamin D deficiency (<12.5 nmol/L) [31].
Pelajo et al. compared two groups, one with and one
without autoimmune disorders [11]. They found that of
those individuals in the autoimmune disorders group,
23% had vitamin D deficiency [serum 25(OH)D < 20 ng/
ml], and of those in the non-autoimmune group, 14%
were vitamin D deficient. Even though there has been
extensive evidence of vitamin D deficiency in association
with autoimmune rheumatologic disorders in adults, lit-
tle information is available relating to children [4].
Despite the methodological limitations of this study
(small sample size, cross-sectional, single-center study(in El ayachi hospital, there is more recruitment of late
and polyarticular forms. however, in paediatric hospital,
they recruit more early and oligoarticular forms which
constitu a bias of recruitment) and absence of control), our
results could support the studies concerning the association
between serum 25(OH)D levels and disease activity in chil-
dren and adolescents with JIA.
Conclusion
Our study showed that three-quarters of children with
JIA had hypovitaminosis D. This study adds evidence to
the growing knowledge regarding vitamin D and auto-
immunity. Additional research, with a larger sample of
children, is needed to confirm our findings.
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